Treatment-experienced patients with moderate to severe atopic dermatitis attained higher efficacy rates on rocatinlimab ...
The American Academy of Dermatology (AAD) meeting last week continued to provide positive news, including from US biotech ...
Amgen and Kyowa Kirin's rocatinlimab showed strong efficacy in Phase 3 trials for atopic dermatitis, achieving key endpoints ...
In September 2024, a readout from a separate trial of rocatinlimab elicited mixed reactions from analysts, who found the ...
Clinical Trials Arena on MSN6d
Amgen and Kyowa Kirin’s rocatinlimab trial for atopic dermatitis meets endpointsAmgen and Kyowa Kirin have reported that the 24-week Phase III IGNITE trial assessing two dose strengths of rocatinlimab, in ...
MedPage Today on MSN6d
T-Cell Rebalancing Therapy Active in Previously Treated Atopic DermatitisTreatment-emergent adverse events (TEAEs) occurred in a similar proportion of patients in each group, and were mostly mild or ...
Amgen and Kyowa Kirin have shared promising results from a phase 3 programme of their investigational T-cell rebalancing ...
Amgen’s $400 million eczema drug candidate has recorded two more phase 3 victories. The data drops provide more evidence that ...
US biotech Amgen (Nasdaq: AMGN) and Japanese partner Kyowa Kirin (TYO: 4151) announced new results from the ongoing ROCKET ...
Amgen & Kyowa Kirin positive results from rocatinlimab phase 3 IGNITE study in adults with moderate to severe atopic dermatitis: Thousand Oaks, California Tuesday, March 11, 2025, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback